RSV vaccine: Beating the virus at its own game

Science Translational Medicine

Volumn 7, Issue 312, 2015, Pages

  Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN;

ANTIBODY TITER; CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; GENETIC PREDISPOSITION; HUMAN; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SHORT SURVEY; VIRAL CLEARANCE; VIRUS ATTENUATION; VIRUS REPLICATION; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY;

HUMANS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL PROTEINS;

EID: 84947237561     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad2515     Document Type: Short Survey

References (10)

1. H. Nair, D. J. Nokes, B. D. Gessner, M. Dherani, S. A. Madhi, R. J. Singleton, K. L. O'Brien, A. Roca, P. F. Wright, N. Bruce, A. Chandran, E. Theodoratou, A. Sutanto, E. R. Sedyaningsih, M. Ngama, P. K. Munywoki, C. Kartasasmita, E. A. Simões, I. Rudan, M. W. Weber, H. Campbell, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375, 1545-1555 (2010).
2. R. A. Karron, C. Luongo, B. Thumar, K. M. Loehr, J. A. Englund, P. L. Collins, U. J. Buchholz, A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci. Transl. Med. 7, 312ra175 (2015).
3. H. W. Kim, J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, R. H. Parrott, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
4. L. J. Anderson, C. A. Heilman, Protective and diseaseenhancing immune responses to respiratory syncytial virus. J. Infect. Dis. 171, 1-7 (1995).
5. C. A. Green, E. Scarselli, C. J. Sande, A. J. Thompson, C. M. de Lara, K. S. Taylor, K. Haworth, M. Del Sorbo, B. Angus, L. Siani, S. Di Marco, C. Traboni, A. Folgori, S. Colloca, S. Capone, A. Vitelli, R. Cortese, P. Klenerman, A. Nicosia, A. J. Pollard, Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7, 300ra126 (2015).
6. G. Taylor, M. Thom, S. Capone, A. Pierantoni, E. Guzman, R. Herbert, E. Scarselli, F. Napolitano, A. Giuliani, A. Folgori, S. Colloca, R. Cortese, A. Nicosia, A. Vitelli, Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci. Transl. Med. 7, 300ra127 (2015).
7. P. F. Wright, R. A. Karron, R. B. Belshe, J. R. Shi, V. B. Randolph, P. L. Collins, A. F. O'Shea, W. C. Gruber, B. R. Murphy, The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25, 7372-7378 (2007).
8. P. L. Collins, R. Fearns, B. S. Graham, Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease. Curr. Top. Microbiol. Immunol. 372, 3-38 (2013).
9. A. Bermingham, P. L. Collins, The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. U.S.A. 96, 11259-11264 (1999).
10. M. N. Teng, S. S. Whitehead, A. Bermingham, M. St Claire, W. R. Elkins, B. R. Murphy, P. L. Collins, Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74, 9317-9321 (2000).